PRESENTATIONSPostinfectious Functional Gastrointestinal DisordersMearin, Fermín MDAuthor Information Institute of Functional and Motor Digestive Disorders Centro Médico Teknon, Barcelona, Spain Supported by Abbott Products Operations AG, Hegenheimermattweg 127, 4123 Allschwil, Switzerland. Conflict of Interest: The author is a speaker for Solvay and Abbott and received sponsorships for organizing scientific events from Solvay and Abbott. Reprints: Fermín Mearin, MD, Institute of Functional and Motor Digestive Disorders, Centro Médico Teknon. Vilana 12, 08022 Barcelona, Spain (e-mail: [email protected]). Journal of Clinical Gastroenterology: August 2011 - Volume 45 - Issue - p S102-S105 doi: 10.1097/MCG.0b013e31821fbf58 Buy Metrics Abstract Functional gastrointestinal disorders are associated with low health-related quality of life and high resource utilization. Postinfectious irritable bowel syndrome (PI-IBS) is a functional gastrointestinal disorder defined as the acute onset of new IBS symptoms in an individual who has not previously met the Rome criteria for IBS, immediately after an acute illness characterized by 2 or more of the following: fever, vomiting, diarrhea, or a positive bacterial stool culture. Although the pathophysiological mechanisms involved in PI-IBS are currently unknown, it is believed that a transitory inflammation leads to subtle but permanent changes in the structure and function of the digestive system that induce symptoms. This review considers recent evidence surrounding the role of inflammatory mediators in the development of hypersensitivity, along with the mediators and mechanisms of abdominal pain and discomfort once the acute inflammation has cleared. Recent data suggest that anatomic changes to mast cells-nerve fibers are necessary, but not sufficient to induce symptoms. It is now possible to estimate the risk of developing PI-FGID based on the presence and relative severity of different risk factors, including prolonged duration of initial illness, toxicity of infecting bacterial strain, smoking, mucosal markers of inflammation, female sex, depression, hypochondriasis, and adverse life events in the preceding 3 months. © 2011 Lippincott Williams & Wilkins, Inc.